Morten Otto Sommer
Fondateur chez Biosyntia ApS
Fortune : 55 710 $ au 30/04/2024
Profil
Dr. Morten Otto A.
Sommer is an Independent Director at Novonesis A/S, a Chairman-Research at SNIPR Biome ApS, a Chief Executive Officer & Director at Biosyntia ApS, a Chairman at Clinical-Microbiomics A/S, a Chief Executive Officer at Manjin ApS, a Chief Executive Officer at Manjin Holding ApS, a Director & Chief Science Officer at UNION Therapeutics A/S and a Professor at Technical University of Denmark.
He is on the Board of Directors at Novonesis A/S, UTILITY therapeutics Ltd., Biosyntia ApS, Snipr Holdings ApS and UNION Therapeutics A/S.
Dr. Sommer was previously employed as an Independent Director by Novozymes A/S, a Chief Executive Officer & Director by Microlytic ApS, a Principal by California Institute of Technology, a Co-Founder by Formbion, a Principal by Harvard University, and a Principal by University of Copenhagen.
He received his graduate degree from the University of Copenhagen and a doctorate degree from Harvard University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,00% | 31/12/2023 | 1 000 ( 0,00% ) | 55 710 $ | 30/04/2024 |
Postes actifs de Morten Otto Sommer
| Sociétés | Poste | Début |
|---|---|---|
Biosyntia ApS
 Biosyntia ApS BiotechnologyHealth Technology Biosyntia ApS provides services in synthetic biology and metabolic engineering fields. It offers biocatalysts for fermentation of fine chemicals. The company was founded by Andreas Hougaard Laustsen, Morten Otto Alexander Sommer, and Hans Jasper Genee in 2012 and is headquartered in Copenhagen, Denmark. | Fondateur | 01/01/2012 |
UNION Therapeutics A/S
 UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | Directeur Technique/Scientifique/R&D | - |
UTILITY therapeutics Ltd.
 UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Fondateur | 01/01/2018 |
SNIPR Biome ApS
 SNIPR Biome ApS Pharmaceuticals: MajorHealth Technology SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark. | Fondateur | 11/08/2017 |
| Technical University of Denmark | Corporate Officer/Principal | - |
Clinical-Microbiomics A/S
 Clinical-Microbiomics A/S BiotechnologyHealth Technology Clinical-Microbiomics A/S is a Danish private company located in Copenhagen with domestic subsidiaries. The firm engages in conducting biotechnology research and experimental development. Anders Grøn is currently the CEO of the company. | Président | - |
| Manjin ApS | Directeur Général | - |
Anciens postes connus de Morten Otto Sommer
| Sociétés | Poste | Fin |
|---|---|---|
Novozymes A/S
 Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Directeur/Membre du Conseil | - |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| ░░░░░░░░░░ ░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░░░ ░░░░░░░░░ ░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░ | ░░░░░░░░░ | - |
Formation de Morten Otto Sommer
| Harvard University | Doctorate Degree |
| University of Copenhagen | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Microlytic ApS
 Microlytic ApS Medical SpecialtiesHealth Technology Microlytic ApS provided structural biology laboratories equipment. It developed its technology solutions to address issues in the structural biology. The company was founded by Morten Otto Alexander Sommer in 2006 and headquartered in Roskilde, Denmark. | Health Technology |
UNION Therapeutics A/S
UNION Therapeutics A/S Pharmaceuticals: MajorHealth Technology Union Therapeutics A/S operates as a clinical stage pharmaceutical company which focuses on the treatment of inflammatory skin disease. It also centers in the development of molecules exhibiting immunological and microbiological effects. The company is headquartered in Hellerup, Denmark. | Health Technology |
| Formbion | |
Biosyntia ApS
Biosyntia ApS BiotechnologyHealth Technology Biosyntia ApS provides services in synthetic biology and metabolic engineering fields. It offers biocatalysts for fermentation of fine chemicals. The company was founded by Andreas Hougaard Laustsen, Morten Otto Alexander Sommer, and Hans Jasper Genee in 2012 and is headquartered in Copenhagen, Denmark. | Health Technology |
UTILITY therapeutics Ltd.
UTILITY therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections. | Health Technology |
Novozymes A/S
Novozymes A/S Chemicals: SpecialtyProcess Industries Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark. | Process Industries |
SNIPR Biome ApS
SNIPR Biome ApS Pharmaceuticals: MajorHealth Technology SNIPR Biome ApS develops bacterial composition to provide treatment for diabetes to cancer. The company was founded by Christian Grøndal and is headquartered in Kongens Lyngby, Denmark. | Health Technology |
Clinical-Microbiomics A/S
Clinical-Microbiomics A/S BiotechnologyHealth Technology Clinical-Microbiomics A/S is a Danish private company located in Copenhagen with domestic subsidiaries. The firm engages in conducting biotechnology research and experimental development. Anders Grøn is currently the CEO of the company. | Health Technology |
| Manjin ApS |
